Pauline Brice

TL;DR: High-dose therapy with ASCT compared to standard treatment prolonged remission and survival after first progression of FL patients and Multivariate analysis of parameters significant according to univariate analysis found that no ASCT at first progression, age at relapse > 50 years, progression on-therapy were adversely significant on survival.

TL;DR: Fewer progressions/relapses were observed with BEACOPP, demonstrating the high efficacy of the more intensive regimen, even in low-risk patients, and additional considerations, balancing treatment-related toxicity and late morbidity due to salvage may help with decision-making with regard to treatment with ABVD.

TL;DR: The IPI was prognostic for OS, but in this population, a very low number of patients belonged to the high-risk groups, so three prognostic factors for poor OS were identified.

TL;DR: Patients with relapsed HL should be identified according to their prognostic factors at relapse (duration of remission and extranodal disease or stage), and the role of tandem HDT or allogeneic SCT should be proposed for patients not in complete remission at the time of HDT.

TL;DR: Observations in highly pretreated HL patients suggest that anti‐PD‐1 therapy might re‐sensitize tumor cells to CT, and salvage therapies for unsatisfactory response to anti‐ PD‐1 should be considered.